Profile data is unavailable for this security.
About the company
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
- Revenue in USD (TTM)3.80m
- Net income in USD-53.40m
- Incorporated2015
- Employees55.00
- LocationCAMP4 Therapeutics CorpOne Kendall SquareBldg 1400 West 3rd FloorCAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 651-8867
- Fax+1 (302) 655-5049
- Websitehttps://www.camp4tx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc | 4.40m | -60.78m | 184.65m | 46.00 | -- | -- | -- | 41.95 | -2.83 | -2.83 | 0.1643 | -0.3213 | 0.0771 | 5.67 | 18.85 | 95,695.65 | -106.49 | -41.57 | -124.80 | -46.86 | 54.73 | 24.70 | -1,380.69 | -2,290.77 | 2.73 | -171.82 | -- | -- | 25.15 | -- | -136.17 | -- | -10.88 | -- |
| Ovid Therapeutics Inc | 6.61m | -36.33m | 184.86m | 23.00 | -- | 2.26 | -- | 27.97 | -0.5112 | -0.5112 | 0.093 | 0.6282 | 0.0794 | -- | -- | 287,391.30 | -43.64 | -13.89 | -49.07 | -15.44 | -- | -- | -549.62 | -40.79 | -- | -- | 0.00 | -- | 44.50 | -- | 49.50 | -- | -7.98 | -- |
| Sol Gel Technologies Ltd | 18.97m | -8.99m | 187.20m | 34.00 | -- | 7.19 | -- | 9.87 | -3.23 | -3.23 | 6.81 | 9.34 | 0.4891 | -- | 2.25 | 557,941.20 | -23.17 | -29.32 | -27.70 | -33.19 | -- | -- | -47.37 | -138.22 | -- | -- | 0.00 | -- | 642.47 | -12.81 | 61.16 | -- | -68.01 | -- |
| Voyager Therapeutics Inc | 31.32m | -126.78m | 188.48m | 172.00 | -- | 0.8556 | -- | 6.02 | -2.17 | -2.17 | 0.5358 | 3.96 | 0.0877 | -- | 2.64 | 182,069.80 | -35.50 | -1.01 | -39.95 | -1.27 | -- | -- | -404.85 | -2.34 | -- | -- | 0.00 | -- | -68.00 | -5.18 | -149.12 | -- | -14.53 | -- |
| Humacyte Inc | 1.57m | -36.97m | 194.93m | 218.00 | -- | -- | -- | 124.08 | -0.2206 | -0.2206 | 0.011 | -0.0299 | 0.0152 | -- | -- | 7,206.42 | -35.84 | -41.46 | -46.28 | -45.37 | 60.53 | -- | -2,353.22 | -8,438.13 | 0.8965 | -- | 1.10 | -- | -- | -- | -34.24 | -- | -28.00 | -- |
| Neonc Technologies Holdings Inc | 59.99k | -48.88m | 199.42m | 3.00 | -- | -- | -- | 3,324.17 | -2.59 | -2.59 | 0.0032 | -0.6067 | 0.0176 | -- | -- | -- | -1,431.87 | -- | -- | -- | 33.34 | -- | -81,472.06 | -- | -- | -22.45 | -- | -- | 17.80 | -- | 20.26 | -- | -- | -- |
| CAMP4 Therapeutics Corp | 3.80m | -53.40m | 199.74m | 55.00 | -- | 3.08 | -- | 52.54 | -2.48 | -2.48 | 0.1746 | 1.25 | 0.0706 | -- | 1.81 | 69,127.27 | -99.11 | -- | -121.32 | -- | -- | -- | -1,404.47 | -- | -- | -- | 0.0013 | -- | 86.29 | -- | -5.07 | -- | -- | -- |
| Inhibikase Therapeutics Inc | 0.00 | -47.66m | 201.90m | 15.00 | -- | 1.71 | -- | -- | -1.15 | -1.15 | 0.00 | 0.9745 | 0.00 | -- | -- | 0.00 | -113.51 | -56.32 | -131.71 | -65.21 | -- | -- | -- | -1,965.97 | -- | -- | 0.00 | -- | -100.00 | -- | -44.62 | -- | -- | -- |
| Alector Inc | 69.05m | -107.74m | 204.11m | 156.00 | -- | 3.48 | -- | 2.96 | -1.07 | -1.07 | 0.6893 | 0.5371 | 0.1622 | -- | -- | 290,117.70 | -25.31 | -19.30 | -34.27 | -23.57 | -- | -- | -156.03 | -108.92 | -- | -- | 0.1428 | -- | 3.60 | 36.50 | 8.70 | -- | -39.33 | -- |
| Arcturus Therapeutics Holdings Inc | 97.60m | -66.71m | 204.85m | 174.00 | -- | 0.8744 | -- | 2.10 | -2.46 | -2.46 | 3.60 | 8.25 | 0.2989 | -- | 5.12 | 560,919.60 | -20.43 | -19.22 | -24.18 | -24.16 | -- | -- | -68.35 | -68.95 | -- | -- | 0.00 | -- | -8.69 | 48.93 | -172.30 | -- | -4.55 | -- |
| Surrozen Inc | 3.60m | -86.91m | 209.83m | 40.00 | -- | -- | -- | 58.22 | -19.76 | -19.76 | 0.6008 | -2.74 | 0.0507 | -- | 0.4882 | 90,100.00 | -122.36 | -60.48 | -134.33 | -68.26 | -- | -- | -2,411.38 | -993.19 | -- | -- | -- | -- | -- | -- | -47.68 | -- | -55.92 | -- |
| Silence Therapeutics plc | 25.81m | -65.01m | 210.19m | 115.00 | -- | 3.06 | -- | 8.14 | -0.462 | -0.462 | 0.1831 | 0.5227 | 0.1383 | -- | 124.98 | -- | -34.83 | -39.00 | -39.01 | -48.09 | 91.20 | 55.91 | -251.86 | -203.50 | -- | -- | 0.00 | -- | 36.71 | 168.26 | 16.45 | -- | 78.99 | -- |
| Heron Therapeutics Inc | 155.10m | -13.58m | 210.87m | 122.00 | -- | 30.02 | -- | 1.36 | -0.0809 | -0.0809 | 0.9199 | 0.0812 | 0.6604 | 0.6977 | 2.09 | 1,271,287.00 | -5.78 | -50.09 | -9.22 | -70.09 | 73.92 | 56.53 | -8.75 | -136.13 | 1.78 | -- | 0.9037 | -- | 13.57 | -0.2317 | 87.72 | -- | -24.93 | -- |
| Context Therapeutics Inc | 0.00 | -26.44m | 211.32m | 12.00 | -- | 2.89 | -- | -- | -0.2835 | -0.2835 | 0.00 | 0.7964 | 0.00 | -- | -- | 0.00 | -31.94 | -44.73 | -33.64 | -57.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.52 | -- | -- | -- |
| Quantum-Si Inc | 3.18m | -116.85m | 213.46m | 143.00 | -- | 0.9076 | -- | 67.19 | -0.6589 | -0.6589 | 0.0176 | 1.09 | 0.0128 | 0.404 | 3.58 | 22,216.78 | -47.06 | -- | -50.90 | -- | 51.65 | -- | -3,677.97 | -11,135.53 | 10.59 | -- | 0.00 | -- | 182.62 | -- | -5.26 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to CAMP4 Therapeutics Corp's reporting currency: US Dollar USD
40.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 6.31m | 13.46% |
| Coastlands Capital LPas of 10 Sep 2025 | 4.89m | 10.42% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 3.02m | 6.45% |
| Adage Capital Management LPas of 30 Sep 2025 | 1.96m | 4.18% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.49m | 3.18% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 389.31k | 0.83% |
| Geode Capital Management LLCas of 31 Dec 2025 | 336.29k | 0.72% |
| Stonepine Capital Management LLCas of 31 Dec 2025 | 228.89k | 0.49% |
| Alyeska Investment Group LPas of 31 Dec 2025 | 200.00k | 0.43% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 172.20k | 0.37% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
